Evidence map›Paper›PMID 39851947›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Long-Term Oncological Outcomes Related to Lymphadenectomy in Clinical Stage I NSCLC: A Multicenter Retrospective Experience.

Beatrice Manfredini, Carmelina Cristina Zirafa, Alessandro Stefani, Gaetano Romano, Greta Alì, Riccardo Morganti, Ilaria Ceccarelli, Federico Davini, Pier Luigi Filosso, Franca Melfi

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Beatrice ManfrediniMinimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy.ORCID 0009-0001-9932-5117
Carmelina Cristina ZirafaMinimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0003-3240-9313
Alessandro StefaniUnit of Thoracic Surgery, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy.
Gaetano RomanoMinimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy.
Greta AlìPathological Anatomy, Surgical, Medical, Molecular and Critical Care Pathology Department, University Hospital of Pisa, 56126 Pisa, Italy.
Riccardo MorgantiSection of Statistics, University Hospital of Pisa, 56126 Pisa, Italy.ORCID 0000-0001-7783-0262
Ilaria CeccarelliMinimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy.ORCID 0009-0004-2967-4153
Federico DaviniMinimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy.
Pier Luigi FilossoUnit of Thoracic Surgery, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy.
Franca MelfiUnit of Thoracic Surgery, Department of Pharmacy and Health and Nutrition Sciences, University of Calabria, 87036 Rende, Italy.ORCID 0000-0002-1773-8269

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLymphadenectomy is considered a key part of the radical treatment of resectable lung cancer, although its appropriate extension in early stages is a debated topic due to the great heterogeneity of studies in the literature. This study aims to evaluate the impact of lymphadenectomy extent on survival and recurrence in the treatment of early-stage NSCLC patients undergoing lobectomy and lymph node dissection.

methodsData from clinical stage I NSCLC patients undergoing lobectomy and hilar-mediastinal lymphadenectomy at two thoracic surgery centers from 2016 to 2019 were retrospectively evaluated. Information regarding perioperative outcomes and lymphadenectomy details was collected and analyzed, and their impact on OS, CSS, and DFS was assessed.

resultsDuring the period under review, 323 patients with stage cI lung cancer underwent lobectomy with lymphadenectomy. Statistical analysis showed that the evaluated lymph nodal factors (mean number of lymph nodes removed and number and type of lymph node station explored) did not statistically significantly impact OS, CSS, and DFS at a median follow-up of 59 months (IQR 45-71).

conclusionsThe results of this study suggest that a less invasive procedure than systematic lymphadenectomy could be performed in early-stage cases with adequate preoperative staging.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsLymph Node ExcisionAgedFemaleHumansMaleMiddle AgedNeoplasm StagingRetrospective StudiesTreatment Outcomeclinical stage Iearly stagelymphadenectomyNSCLC

Identifiers

PMID39851947
PMCPMC11763634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.